This CPB has been revised to restructure the medical necessity criteria for the following: leuprolide, Lupron Depot, Eligard, Zoladex, Vantas, Supprelin LA, Trelstar, Triptodur, Lupaneta Pack, Cetrorelix (Cetrotide), Ganirelix, and Synarel. This CPB has been revised to (i) add dosing recommendations for Lupron depot, Trelstar, Triptodur, and Vantas; and (ii) state  Zoladex is considered medically necessary for the prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias. This CPB has been revised to provide criteria for the continued medical necessity of gonadotropin-releasing hormone analogs for prostate cancer (Eligard, Firmagon, Leuprolide, Lupron Depot, Trelstar, Vantas, Zoladex), salivary gland tumors (Eligard, Leuprolide, Lupron Depot), and gender dysphoria (Eligard, Lupron Depot, Supprelin LA, Trelstar, Triptodur, Vantas, Zoladex).